Brief: Cerenis Therapeutics Holding Announces First Results Of Target Phase II Study

Abionyx Pharma SA

25/06/2018 18:02

June 25 (Reuters) - CERENIS THERAPEUTICS HOLDING SA  CEREN.PA :
    * FIRST RESULTS OF TARGET PHASE II STUDY DEMONSTRATE THE ABILITY OF CER-001, AN HDL MIMETIC,
TO
TARGET TUMOR IN PATIENTS WITH ESOPHAGEAL CANCER
    * PRIMARY OBJECTIVE MET: CLINICALLY MEANINGFUL TARGETING OF ESOPHAGEAL TUMOR TISSUE BY
LABELED
CER-001
    * THE SUSTAINED TUMOR LABELING SUPPORTS FUTURE USE OF HDL MIMETICS TO IMPROVE EFFECTIVE
DELIVERY
OF THERAPEUTIC AGENTS
    * RESULTS ARE CONSISTENT WITH PRECLINICAL STUDIES USING HDL MIMETICS
    * NO SAFETY OR TOLERABILITY ISSUES WERE OBSERVED
    * FINAL ANALYSIS RESULTS ARE NOT EXPECTED TO DIFFER FROM THIS PRELIMINARY ANALYSIS
    * FULL RESULTS WILL BE COMMUNICATED AND PRESENTED AT FUTURE MEDICAL CONFERENCES.

Source text for Eikon:  ID:nNDL9Y9QpD 
Further company coverage:  CEREN.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))